The benchmark Sensex on Wednesday rose for a second consecutive session to close at its highest in almost a year as pharma stocks led by Glenmark Pharmaceuticals and Aurobindo Pharma gained after getting approvals for generic versions of a blockbuster cholesterol drug in the US.
Advertisement
Quoting IMS sales data for the 12 months to May 2016, Sun Pharma said Rosuvastatin calcium tablets achieved annual sales of around $6.78 billion. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
The BSE index rose 0.46 percent to 27,915.89.
Both Sun and Glenmark said the approvals for their generic rosuvastatin calcium tablets have been granted to their subsidiaries in the US.
The shares of the company advanced 2.78 percent on Wednesday.
The broader NSE index gained 0.44 percent to 8,565.85, its highest close since August 6.
Overseas, Asian shares ended mixed, while European stock opened higher as investors struck cautiously optimistic tone ahead of European Central Banks (ECB) meeting tomorrow. Singapore, Japan, Kopsi and Taiwan were down 0.29 per cent, 0.25 per cent, 0.07 per cent and 0.30 per cent, respectively, while, Hong Kong and China gained 0.97 per cent and 0.90 per cent. The current market cap of the company is Rs. 47267.07 crore.
Advertisement
Aurobindo, Glenmark and Sun Pharma got USFDA nod to sell Crestor in the United States market.
